BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7749984)

  • 1. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).
    Riley JL; Westerheide SD; Price JA; Brown JA; Boss JM
    Immunity; 1995 May; 2(5):533-43. PubMed ID: 7749984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
    Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
    Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.
    Brown JA; Rogers EM; Boss JM
    Nucleic Acids Res; 1998 Sep; 26(18):4128-36. PubMed ID: 9722631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Steimle V; Otten LA; Zufferey M; Mach B
    Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer.
    Taxman DJ; Cressman DE; Ting JP
    J Immunol; 2000 Aug; 165(3):1410-6. PubMed ID: 10903745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
    Zhou H; Glimcher LH
    Immunity; 1995 May; 2(5):545-53. PubMed ID: 7749985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
    Masternak K; Muhlethaler-Mottet A; Villard J; Zufferey M; Steimle V; Reith W
    Genes Dev; 2000 May; 14(9):1156-66. PubMed ID: 10809673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X box-like sequences in the MHC class II region maintain regulatory function.
    Gomez JA; Majumder P; Nagarajan UM; Boss JM
    J Immunol; 2005 Jul; 175(2):1030-40. PubMed ID: 16002703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
    Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
    J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class II transactivator is required for maximal expression of HLA-DOB in B cells.
    Nagarajan UM; Lochamy J; Chen X; Beresford GW; Nilsen R; Jensen PE; Boss JM
    J Immunol; 2002 Feb; 168(4):1780-6. PubMed ID: 11823510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
    Masternak K; Reith W
    EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.
    Peijnenburg A; Van den Berg R; Van Eggermond MJ; Sanal O; Vossen JM; Lennon AM; Alcaïde-Loridan C; Van den Elsen PJ
    Immunogenetics; 2000 Jan; 51(1):42-9. PubMed ID: 10663561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.
    Kern I; Steimle V; Siegrist CA; Mach B
    Int Immunol; 1995 Aug; 7(8):1295-9. PubMed ID: 7495736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by the class II transactivator and the thyroid Y box protein.
    Montani V; Taniguchi SI; Shong M; Suzuki K; Ohmori M; Giuliani C; Napolitano G; Saji M; Fiorentino B; Reimold AM; Ting JP; Kohn LD; Singer DS
    Endocrinology; 1998 Jan; 139(1):280-9. PubMed ID: 9421426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
    Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
    Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
    Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
    J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.
    Chin KC; Mao C; Skinner C; Riley JL; Wright KL; Moreno CS; Stark GR; Boss JM; Ting JP
    Immunity; 1994 Nov; 1(8):687-97. PubMed ID: 7600294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of MHC class I expression by the MHC class II transactivator CIITA.
    Martin BK; Chin KC; Olsen JC; Skinner CA; Dey A; Ozato K; Ting JP
    Immunity; 1997 May; 6(5):591-600. PubMed ID: 9175837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA.
    Quan V; Towey M; Sacks S; Kelly AP
    Immunogenetics; 1999 Oct; 49(11-12):957-63. PubMed ID: 10501838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.
    Yun S; Gustafsson K; Fabre JW
    Transplantation; 1998 Jul; 66(1):103-11. PubMed ID: 9679829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.